10 Results

People

  1. Traina
    Traina
  2. Modi
    Modi
  3. Dang
    Dang
  4. Gucalp
    Gucalp
  5. Fornier
    Fornier
  6. Goldfarb
    Goldfarb
  7. Hudis
    Hudis
  8. Iyengar
    Iyengar
  9. Jochelson
    Jochelson
  10. Lake
    Lake

Groups

  1. Breast Medicine Service (10)
  2. Department of Medicine (10)
  3. Epidemiology and Biostatistics (10)
  4. Molecular Imaging and Therapy Service (10)
  5. Radiology, Department of (10)
  6. Solid Tumor Oncology Division (10)
  7. Survivorship Research (10)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (9)
  9. Population Sciences Research Program (9)
  10. Biostatistics Service (6)
  1. "Molecular Imaging and Therapy Service"
  2. "Breast Medicine Service"
  3. "Tiffany Traina"
Formats
  1. Meeting Abstract (8)
  2. Journal Article (2)
Groups
  1. Breast Medicine Service (10)
  2. Department of Medicine (10)
  3. Epidemiology and Biostatistics (10)
  4. Molecular Imaging and Therapy Service (10)
  5. Radiology, Department of (10)
  6. Solid Tumor Oncology Division (10)

More Groups

People
  1. Tiffany Traina (10)
  2. Shanu Modi (9)
  3. Ayca Gucalp (8)
  4. Chau Dang (8)
  5. Clifford Hudis (6)
  6. Diana Lake (6)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2021 (1)
  4. 2019 (1)
  5. 2017 (4)
  6. 2016 (1)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (3)
  2. Annals of Oncology (2)
  3. Cancer Research (2)
  4. JAMA Network Open (1)
  5. Journal of Clinical Oncology (1)
  6. Lancet (1)
Publishers
  1. Elsevier Inc. (3)
  2. American Association for Cancer Research (2)
  3. Oxford University Press (2)
  4. American Medical Association (1)
  5. American Society of Clinical Oncology (1)
  6. Elsevier Science, Inc. (1)

Results (10)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): An open-label, randomised, controlled, phase 2 study
    Journal Article

    Tsai, C. J.; Yang, J. T.; Shaverdian, N.; Patel, J.; Shepherd, A. F.; Eng, J.; Guttmann, D.; Yeh, R.; Gelblum, D. Y.; Namakydoust, A.; more...
    Lancet (2024)

    Fulltext@MSK | Save
  • Final analysis of consolidative use of radiotherapy to block (CURB) oligoprogression trial - A randomized study of stereotactic body radiotherapy for oligoprogressive metastatic lung and breast cancers
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Eng, J.; Yeh, R.; Girshman, J.; Das, J.; Gelblum, D.; Xu, A. J.; more...
    International Journal of Radiation Oncology, Biology, Physics (2022)

    Fulltext@MSK | Save
  • Consolidative use of radiotherapy to block (CURB) oligoprogression: Interim analysis of the first randomized study of stereotactic body radiotherapy in patients with oligoprogressive metastatic cancers of the lung and breast
    Meeting Abstract

    Tsai, C. J.; Yang, J. T.; Guttmann, D. M.; Shaverdian, N.; Shepherd, A. F.; Eng, J.; Gelblum, D.; Xu, A. J.; Namakydoust, A.; Iqbal, A.; more...
    International Journal of Radiation Oncology, Biology, Physics (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of gemcitabine with trastuzumab and pertuzumab after prior pertuzumab-based therapy among patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A phase 2 clinical trial
    Journal Article

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Fornier, M. N.; Goldfarb, S.; Jhaveri, K.; more...
    JAMA Network Open (2019)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P. A.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Quantifying the incidence of homologous recombination repair status in metastatic triple negative breast cancer receiving concurrent cisplatin and radiation therapy
    Meeting Abstract

    Powell, S. N.; Gucalp, A.; Traina, T. A.; Patil, S.; Wilgucki, M.; Arnold, B. B.; Cahlon, O.; Delsite, R.; Ulaner, G. A.; Ho, A. Y.
    International Journal of Radiation Oncology, Biology, Physics (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L. M.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S. B.; more...
    Annals of Oncology (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-Positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J. C.; Traina, T. A.; DeFusco, P.; Dickler, M. N.; Fornier, M. N.; Goldfarb, S.; more...
    Cancer Research (2017)

    Fulltext@MSK | Save
  • Phase II study of gemcitabine, trastuzumab, and pertuzumab for HER2-positive metastatic breast cancer after prior pertuzumab-based therapy
    Meeting Abstract

    Iyengar, N. M.; Smyth, L.; Lake, D.; Gucalp, A.; Singh, J.; Traina, T. A.; Defusco, P.; Dickler, M. N.; Fornier, M.; Goldfarb, S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer with cardiac biomarker data
    Meeting Abstract

    Iyengar, N. M.; Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; more...
    Cancer Research (2013)

    Fulltext@MSK | Save